Minerva Neurosciences (NASDAQ:NERV) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a sell rating in a research note released on Sunday morning.

A number of other brokerages also recently issued reports on NERV. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, December 29th. HC Wainwright lowered their target price on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $4.00.

Minerva Neurosciences Stock Down 1.2%

NERV opened at $4.27 on Friday. Minerva Neurosciences has a twelve month low of $1.15 and a twelve month high of $12.46. The company has a fifty day moving average of $4.00 and a 200-day moving average of $2.97. The stock has a market cap of $184.78 million, a PE ratio of -2.31 and a beta of -0.28.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). Sell-side analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC grew its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,314 shares of the biopharmaceutical company’s stock after acquiring an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent filing with the Securities & Exchange Commission. 34.56% of the stock is owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.